Roche plans for more convenient-to-use Herceptin and Rituxan.
Ratner
Mark
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000737:chemistry*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D004339:Drug Compounding / Q000379:methods*; D004867:Equipment Design; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D000069283:Rituximab; D013594:Syringes; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D000068878:Trastuzumab